Alzheimer's Symptomatic Treatment Development

PROGRAM

Program

Preclinical studies


In vitro experiments:  Demonstrate the treatment’s neuron-level mechanism of action by modifying neuron excitability and activity with CRISPR.  Time frame:  2020

 

In vivo experiments:  Establish the treatment’s efficacy in mammals by using behavioral tests for measuring cognitive ability in laboratory animals receiving the gene therapy.  Time frame:  2020

Clinical trials

Phase 1 Safety:  Determine safety and dosage in 20-50 healthy adult volunteers for an RNA version of the therapy with temporary effects.  Monitor subjects to learn more about how the therapy works in the body and the effects associated with increased dosage.  Gain early information about efficacy and how best to administer the treatment to limit risks and maximize benefits.  Time frame:  2021 


Phase 2 Efficacy: Measure the RNA therapy’s efficacy in relieving Alzheimer’s symptoms in a group of several hundred patients at the early and moderate stages of the disease.  Closely monitor subjects to identify any side effects.  Time frame:  2022


Phase 3 Efficacy and adverse reactions:  Measure the RNA therapy’s efficacy in relieving Alzheimer’s symptoms in a group of 300 to 3000 patients at the early and moderate stages of the disease.  Closely monitor subjects to identify any side effects.  Time frame:  2023

Cognigenics, LLC

1390 N. McDowell Blvd., Suite G317

Petaluma, California 94954   USA

Voice: 1-772-324-8800

Email: office@cognigenics.co

Subscribe to our newsletter

© 2020 Cognigenics, LLC  All rights reserved.